Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (ALISON)

    Pers / media: Expert CommentPopular

    Periode4-feb-2021

    Mediabijdrages

    2

    Mediabijdrages

    • TitelPhase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (ALISON)
      Mate van erkenningInternational
      Media naam/outletClinicalTrials.gov
      MediatypeWeb
      Release datum04/02/2021
      URLhttps://www.clinicaltrials.gov/ct2/show/NCT04739527
      PersonenAnnegé Vledder
    • TitelPhase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
      Mate van erkenningInternational
      Media naam/outletTrial bulletin
      MediatypeWeb
      Release datum04/02/2021
      URLhttps://trialbulletin.com/lib/entry/ct-04739527
      PersonenAnnegé Vledder